Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria.

Wimo A, Ballard C, Brayne C, Gauthier S, Handels R, Jones RW, Jonsson L, Khachaturian AS, Kramberger M.

J Intern Med. 2014 Mar;275(3):304-16. doi: 10.1111/joim.12167.

2.
3.

Diagnosis and management of Alzheimer's disease: past, present and future ethical issues.

Gauthier S, Leuzy A, Racine E, Rosa-Neto P.

Prog Neurobiol. 2013 Nov;110:102-13. doi: 10.1016/j.pneurobio.2013.01.003. Epub 2013 Apr 8. Review.

PMID:
23578568
4.

Economic considerations of Alzheimer's disease and related disorders.

Michel JP, Zekry D, Mulligan R, Giacobini E, Gold G.

Aging (Milano). 2001 Jun;13(3):255-60. Review.

PMID:
11442307
5.

International Psychogeriatric Association consensus statement on defining and measuring treatment benefits in dementia.

Katona C, Livingston G, Cooper C, Ames D, Brodaty H, Chiu E.

Int Psychogeriatr. 2007 Jun;19(3):345-54. Epub 2007 Mar 27.

PMID:
17386120
6.
7.

Recommendations for best practices in the treatment of Alzheimer's disease in managed care.

Fillit HM, Doody RS, Binaso K, Crooks GM, Ferris SH, Farlow MR, Leifer B, Mills C, Minkoff N, Orland B, Reichman WE, Salloway S.

Am J Geriatr Pharmacother. 2006;4 Suppl A:S9-S24; quiz S25-S28.

PMID:
17157793
8.

Advances in the prevention of Alzheimer's disease and dementia.

Solomon A, Mangialasche F, Richard E, Andrieu S, Bennett DA, Breteler M, Fratiglioni L, Hooshmand B, Khachaturian AS, Schneider LS, Skoog I, Kivipelto M.

J Intern Med. 2014 Mar;275(3):229-50. doi: 10.1111/joim.12178.

9.

Impact of early intervention and disease modification in patients with predementia Alzheimer's disease: a Markov model simulation.

Budd D, Burns LC, Guo Z, L'italien G, Lapuerta P.

Clinicoecon Outcomes Res. 2011;3:189-95. doi: 10.2147/CEOR.S22265. Epub 2011 Oct 7.

10.

Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer's disease.

Gustavsson A, Green C, Jones RW, Förstl H, Simsek D, de Reydet de Vulpillieres F, Luthman S, Adlard N, Bhattacharyya S, Wimo A.

Alzheimers Dement. 2017 Mar;13(3):312-321. doi: 10.1016/j.jalz.2016.12.005. Epub 2017 Jan 5.

PMID:
28063281
11.

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.

Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, Moride Y.

Clin Ther. 2002 Jun;24(6):862-86; discussion 837. Review.

PMID:
12117079
12.

Diagnosing Alzheimer's disease: a systematic review of economic evaluations.

Handels RL, Wolfs CA, Aalten P, Joore MA, Verhey FR, Severens JL.

Alzheimers Dement. 2014 Mar;10(2):225-37. doi: 10.1016/j.jalz.2013.02.005. Epub 2013 May 30. Review.

PMID:
23727080
13.

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH.

Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21.

14.

Cost and care of patients with Alzheimer's disease: clinical predictors in German health care settings.

Reese JP, Hessmann P, Seeberg G, Henkel D, Hirzmann P, Rieke J, Baum E, Dannhoff F, Müller MJ, Jessen F, Geldsetzer MB, Dodel R.

J Alzheimers Dis. 2011;27(4):723-36. doi: 10.3233/JAD-2011-110539.

PMID:
21876256
16.

2012 Alzheimer's disease facts and figures.

Alzheimer's Association.

Alzheimers Dement. 2012;8(2):131-68. doi: 10.1016/j.jalz.2012.02.001.

PMID:
22404854
17.

Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints.

Macklin EA, Blacker D, Hyman BT, Betensky RA.

J Alzheimers Dis. 2013;36(3):475-86. doi: 10.3233/JAD-122212.

18.

Assessing health economic outcome in Alzheimer's disease clinical trials.

Jonsson L.

J Nutr Health Aging. 2007 Jul-Aug;11(4):353-5. Review.

PMID:
17653498
20.

Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia.

Versijpt J.

J Alzheimers Dis. 2014;42 Suppl 3:S19-25. doi: 10.3233/JAD-132639. Review.

PMID:
25061049

Supplemental Content

Support Center